CMS to work close­ly with FDA on ac­cel­er­at­ed ap­proval pay­ment re­forms

The FDA has his­tor­i­cal­ly not dealt with drug pric­ing, un­less it’s re­lat­ed to sav­ings from gener­ic drug com­pe­ti­tion.

But that’s slow­ly chang­ing now, with CMS say­ing it will work close­ly with the US drug reg­u­la­tor on both a new pi­lot project to try to save the fed­er­al gov­ern­ment on ac­cel­er­at­ed ap­proval drugs, and on im­ple­ment­ing the In­fla­tion Re­duc­tion Act, which will es­tab­lish new gov­ern­ment price ne­go­ti­a­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.